Wheezing
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Wheezing is an emerging landscape with 24 programs across 10 companies. The most active players are OM Pharma SA, AstraZeneca, Salix. 11 therapies are approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Cholecalciferol
Hyundai Pharmaceutical Co., LTD.
Prednisolone
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fluticasone Propionate Nebulization
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Budesonide Nebulization
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Fluticasone Propionate
GSK
Analysis
Modality Breakdown
92%
Small molecule
23 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 93% of 27 pipeline programs.
Analysis
Trial Status
26
clinical trials
Clinical Trials
Trial Activity
26 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)